MetaMol Theranostics metamol.com


MetaMol aims to develop diagnostics for the ability of cancer to spread and to supplement existing cancer therapies with anti-metastasis drugs.

MetaMol aims to develop diagnostics for the ability of cancer to spread and to supplement existing cancer therapies with anti-metastasis drugs.

Company (Alive / Active)

Phone:

Fax:

Cincinnati, 45201
Ohio, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
MetaMol Theranostics $0M Nov 30, 2018
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related MetaMol Theranostics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Canary Foundation

San Jose, California, United States
Alive / ActiveCanary Foundation was founded in 2004 by Don Listwin, a successful high-technology executive who lost his mother to misdiagnosed ovarian cancer. Don discovered that although almost $10 billion is spent annually on cancer research in the United States, the vast majority is allocated to developing new cancer treatments and caring for patients. Surprisingly, little funding is available to researchers investigating new ways to detect cancer it at its earliest, curable stages. Don made a commitment ...Show allLogin to see details

Tethys Bioscience

Emeryville, California, United States
Dead / InactiveTethys Bioscience is engaged in efforts to create and commercialize blood tests that accurately assess imminent disease risk with an aim of helping physicians preempt the onset of chronic cardiometabolic conditions by focusing healthcare resources on those patients who will benefit the most from early and aggressive intervention. Tethys Bioscience was established in 2005 with initial attention to type 2 diabetes, pursuing the development of an approach designed to transform the way diabetes a...Show allLogin to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Peptide sequence that promotes tumor invasion Aug 10, 2010 Mar 03, 2015 Patent
Peptide sequence that promotes tumor invasion Nov 14, 2006 Oct 05, 2010 Patent